Ebola: towards the creation of a global vaccine reserve
A WHO employee prepares a vaccine against the Ebola virus in Mbandaka, DRC.
AP - Sam Mednick
Text by: RFI Follow
2 min
By ordering 500,000 doses of the Ebola vaccine, the Gavi Vaccine Alliance intends to build up a stockpile to deal with any resurgence of the disease.
Publicity
Read more
Prequalified by the WHO in November 2019, approved in the wake of the main health agencies,
Ervebo, the anti-Ebola vaccine developed by the Merck laboratory
has already been administered to more than 300,000 people in the Democratic Republic of the Congo and in the countries neighbors.
He played his role in coming to terms with the epidemic that hit the provinces of North Kivu and Ituri until last June.
With the creation of this stock of 500,000 doses,
the Gavi Vaccine Alliance
intends to face future crises.
It will still take a few years to build up these reserves, but they will then be made available free of charge to countries that need them if the virus reappears.
Several other vaccines against Ebola
are in development, including one developed by the Johnson & Johnson laboratory which had been authorized in the Democratic Republic of the Congo.
However, it is not yet prequalified by the WHO, but could be part of the stocks constituted by Gavi once this stage has been completed.
Newsletter
Receive all international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
Africa
Ebola
Health and medicine
DRC